drugset
drugset / Trial / NCT06970782

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

NCT06970782 ↗

Phase 3 Not yet recruiting 278 enrolled Avistone Biotechnology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure

Timeline

Start
2025-05-15
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 5 unknown Intravenous
Comparator Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject PLB1004 Small molecule 80 mg Oral
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Vebreltinib Small molecule 150 mg Oral

Indications

non-small cell lung carcinoma